lung
injuri
fibrosi
repres
signific
outcom
sever
acut
lung
disord
includ
howev
still
effect
drug
treat
lung
injuri
fibrosi
studi
report
gener
clinicalgrad
human
embryon
stem
cell
hesc
deriv
immunityand
matrixregulatori
cell
imrc
manufactur
good
manufactur
practic
gmp
requir
treat
lung
injuri
fibrosi
vivo
gener
imrc
sequenti
differenti
hesc
xenofre
reagent
imrc
possess
uniqu
gene
express
profil
distinct
umbil
cord
mesenchym
stem
cell
ucmsc
higher
level
prolif
immunomodulatori
antifibrot
gene
moreov
intraven
deliveri
imrc
inhibit
pulmonari
inflamm
fibrosi
mous
model
lung
injuri
significantli
improv
surviv
rate
recipi
mice
dosedepend
manner
like
paracrin
function
imrc
superior
primari
ucmsc
fdaapprov
pirfenidon
excel
efficaci
safeti
profil
mice
monkey
two
sever
ill
patient
pilot
studi
light
recent
public
health
crise
involv
pneumonia
acut
lung
injuri
ali
acut
respiratori
distress
syndrom
ard
find
indic
imrc
readi
clinic
trial
lung
disord
determin
secret
human
cell
cultur
supernat
collect
hour
cultur
level
human
protein
measur
human
elisa
kit
cusabio
wuhan
china
accord
manufactur
instruct
concentr
expandbio
beij
china
expandbio
mous
lung
homogen
measur
use
elisa
kit
accord
manufactur
instruct
determin
activ
human
cell
cultur
supernat
collect
hour
cultur
activ
human
measur
sensolyt
plu
assay
kit
immunofluoresc
stain
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
cell
fix
paraformaldehyd
min
permeabil
triton
min
block
bsa
min
room
temperatur
cell
stain
usa
membran
block
room
temperatur
bsa
h
incub
overnight
primari
antibodi
rabbit
collagen
antibodi
cell
signal
technolog
mous
ecadherin
antibodi
abcam
mous
antibodi
aldrich
membran
wash
tbst
time
incub
h
secondari
antibodi
antimous
igg
antibodi
hrd
sigmaaldrich
antirabbit
igg
antibodi
hrd
sigmaaldrich
room
temperatur
imag
obtain
use
chemidoc
xr
imag
system
biorad
quantifi
use
quantiti
one
softwar
soft
agaros
gel
prepar
accord
previous
publish
protocol
cell
harvest
dilut
cell
concentr
ml
mix
agaros
mixtur
cultur
authorfund
right
reserv
reus
allow
without
permiss
infus
cynomolgu
monkey
year
old
singl
intraven
infus
month
bodi
weight
ophthalmolog
statu
hematolog
blood
chemistri
urin
chemistri
measur
longterm
toxic
test
high
dose
low
dose
imrc
salin
inject
cynomolgu
monkey
year
old
intraven
infus
week
time
bodi
weight
bodi
temperatur
food
intak
organ
weight
measur
wholegenom
sequenc
data
produc
hiseq
xten
annoroad
gene
technolog
co
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
ltd
use
analyz
singl
nucleotid
mutat
chang
imrc
hesc
previous
describ
wholegenom
sequenc
data
map
refer
genom
bwa
version
use
mem
mode
default
paramet
genom
coverag
calcul
bedtool
normal
coverag
depth
bin
calcul
divid
raw
coverag
depth
averag
sequenc
depth
duplic
read
remov
uniqu
map
read
retain
copynumb
variat
cnv
analysi
chromosom
sequenc
place
bin
kb
length
repeat
region
annot
genom
repeatmask
http
www
repeatmaskerorg
remov
genom
sequenc
calcul
coverag
cnv
scatterplot
drawn
use
mous
lung
histolog
perform
follow
briefli
lung
dehydr
paraffinembed
cut
section
lung
section
stain
h
e
masson
trichrom
stain
assess
patholog
chang
immunohistochem
stain
perform
use
antibodi
servicebio
wuhan
china
fibronectin
servicebio
collagen
servicebio
gfp
servicebio
immunofluoresc
stain
perform
use
antibodi
gfp
servicebio
servicebio
spc
millipor
imrc
label
lipophil
nearinfrar
fluoresc
dye
indotricarbocyanin
iodid
dir
yeasen
shanghai
china
imrc
suspend
concentr
cell
ml
incub
dir
buffer
min
accord
manufactur
protocol
incub
cell
centrifug
rpm
min
wash
twice
pb
resuspens
imrc
preheat
infus
dirlabel
unlabel
cell
salin
inject
via
tail
vein
mice
lightli
anesthet
monitor
use
vivo
imag
system
day
day
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
day
day
day
day
day
day
day
day
day
day
tail
intraven
inject
dirlabel
imrc
cell
salin
serial
fluoresc
imag
also
obtain
major
organ
ex
vivo
order
reduc
autofluoresc
ideal
filter
condit
dir
imag
excitationemiss
spectrum
near
infrar
rang
nm
flexiventfx
experiment
platform
set
accord
manufactur
instruct
twentyfirst
day
pentobarbit
sodium
mgkg
intraperiton
inject
anesthesia
mice
fix
supin
within
five
eight
minut
endotrach
intub
insert
middl
tracheotomi
comput
process
indic
lung
function
requir
obtain
includ
inspiratori
capac
ic
respiratori
resist
rr
static
complianc
cr
elast
resist
er
newtonian
resist
tissu
damp
g
tissu
elast
h
forc
vital
capac
fvc
lung
tissu
complet
remov
weigh
electron
balanc
lung
coeffici
calcul
accord
formula
wet
lung
weight
g
total
bodi
weight
kg
blm
mous
model
gener
intratrach
inject
mgkg
bleomycin
sulphat
blm
bioway
china
normal
salin
light
anaesthesia
imrc
deliv
intraven
day
day
day
day
injuri
mice
euthan
mgml
sodium
pentobarbit
g
weight
accord
publish
guidelin
anim
kill
day
blm
injuri
perfus
normal
salin
left
lung
use
morphometr
analysi
right
lung
remov
use
analys
mous
ct
scan
perform
accord
manufactur
instruct
compassion
use
studi
two
sever
ill
patient
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
conduct
pilot
studi
use
gmpgrade
imrc
expand
access
program
compassion
use
patient
pilot
studi
approv
ethic
committe
studi
hescderiv
imrc
gener
passag
cell
migrat
human
embryoid
bodi
heb
use
xenofre
reagent
fig
clinic
hesc
line
prepar
describ
previous
clinic
hesc
maintain
essenti
tm
basal
medium
vitronectinco
plate
dissoci
small
clump
form
heb
day
heb
transfer
onto
vitronectinco
plate
cultur
addit
day
heb
outgrowth
cell
dissoci
passag
continu
imrc
medium
passag
imrc
harvest
character
imrc
possess
fibroblastlik
morpholog
fig
maintain
diploid
karyotyp
passag
fig
moreov
copynumb
variat
analysi
whole
genom
sequenc
data
also
indic
chromosom
aneuploidi
larg
delet
duplic
fragment
detect
fig
next
analyz
express
profil
mscspecif
gene
fig
imrc
show
pattern
greatli
differ
hesc
close
resembl
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
primari
umbil
cordderiv
msc
ucmsc
pluripot
gene
nanog
mesendoderm
gene
ectoderm
gene
gfap
extinguish
imrc
ucmsc
fig
imrc
express
mscspecif
gene
includ
pdgfra
sparc
mscspecif
surfac
marker
eng
flow
cytometri
analysi
confirm
surfac
marker
profil
fig
b
contrast
imrc
neg
hematopoiet
surfac
marker
ptprc
imrc
display
abil
undergo
trilineag
differenti
mesenchym
tissu
adipos
cartilag
bone
cell
fig
prolifer
rate
imrc
higher
ucmsc
passag
suggest
imrc
stronger
capac
longterm
selfrenew
fig
interestingli
imrc
gener
smaller
ucmsc
fig
suggest
imrc
pass
smaller
blood
vessel
capillari
easili
thu
may
less
like
caus
pulmonari
embol
evalu
clinic
potenti
imrc
measur
viabil
imrc
suspend
publish
clinic
inject
buffer
found
viabil
imrc
remain
higher
ucmsc
fig
clarifi
degre
similar
hesc
imrc
primari
ucmsc
whole
transcriptom
level
perform
genomewid
profil
imrc
ucmsc
compar
gene
express
hesc
wholetranscriptom
analysi
confirm
imrc
cluster
togeth
ucmsc
unsupervis
hierarch
cluster
fig
accordingli
mscspecif
gene
eng
pdgfra
sparc
upregul
wherea
pluripot
gene
extinguish
imrc
rel
hesc
overal
correl
hesc
weak
r
fig
next
analyz
express
gene
specif
imrc
compar
ucmsc
fig
overal
correl
ucmsc
stronger
r
also
found
mani
gene
differenti
express
imrc
compar
ucmsc
upregul
gene
promot
immunomodul
lif
tissu
repair
vegfa
cell
divis
antifibrosi
contrast
downregul
gene
predominantli
promot
inflamm
fig
gene
set
enrich
analysi
gsea
differenti
express
gene
confirm
imrc
manifest
reduc
inflamm
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
stronger
prolif
capac
top
gene
signatur
compar
primari
ucmsc
fig
e
elucid
heterogen
gene
express
amongst
imrc
singl
cell
rna
sequenc
scrnaseq
perform
imrc
primari
ucmsc
scrnaseq
data
also
show
imrc
rel
homogen
express
mscspecif
marker
pdgfra
sparc
eng
imrc
also
rel
homogen
suppress
pluripot
nonmesenchym
marker
rel
hesc
ucmsc
suggest
like
similar
biolog
activ
primari
msc
transplant
fig
result
provid
insight
clinic
applic
imrc
especi
regard
complet
loss
pluripot
gain
hyperimmunomodulatori
potenti
test
immunomodulatori
capac
imrc
expos
proinflammatori
cytokin
found
stimul
primari
ucmsc
imrc
display
similar
characterist
morpholog
chang
fig
stimul
also
potent
upregul
express
primari
ucmsc
imrc
much
significantli
imrc
fig
import
indoleamin
shown
mediat
immunosuppress
cellinflam
microenviron
catabol
tryptophan
thu
suppress
tryptophankynureninearyl
hydrocarbon
receptor
trpkynahr
pathway
cell
character
imrc
molecular
level
conduct
genomewid
rna
profil
compar
imrc
ucmsc
stimul
fig
hierarch
cluster
reveal
imrc
cluster
separ
ucmsc
although
appear
similar
stimul
fig
analys
imrc
stimul
greater
detail
separ
differenti
express
gene
differ
categori
test
overlap
use
venn
diagram
analysi
fig
found
proinflammatori
gene
show
lower
express
proregen
gene
show
higher
express
level
imrc
compar
primari
ucmsc
fig
confirm
find
perform
focus
elisa
analysi
biolog
relev
chemokin
cytokin
secretom
stimul
imrc
ucmsc
found
least
nine
proinflammatori
cytokin
lower
imrc
ucmsc
includ
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
tumor
necrosi
factor
alpha
tnfa
groa
fig
fig
furthermor
antiinflammatori
lower
immunomodulatori
cytokin
lif
rant
higher
imrc
ucmsc
fig
amongst
regen
cytokin
found
gmcsf
similar
vegfa
mig
higher
imrc
ucmsc
fig
result
indic
imrc
manifest
much
stronger
immunomodulatori
proregen
function
ucmsc
scrnaseq
result
also
indic
imrc
express
compar
primari
ucmsc
fig
similarli
gene
express
analysi
rtqpcr
show
imrc
express
much
higher
level
hesc
ucmsc
human
foreskin
fibroblast
hff
fig
could
detect
highli
secret
protein
condit
media
imrc
elisa
fig
addit
secret
enzymat
activ
correctli
process
isoform
fig
e
investig
role
imrc
fibrosi
human
epitheli
cell
line
use
establish
vitro
fibrosi
model
morpholog
cell
becam
myofibroblastlik
treatment
ngml
fig
consist
morpholog
chang
express
myofibroblast
marker
collagen
collagen
ii
fibronectin
increas
express
epitheli
ident
marker
extinguish
suggest
cell
undergon
myofibroblast
transdifferenti
fig
immunofluoresc
western
blot
analys
confirm
induc
upregul
collagen
downregul
ecadherin
fig
result
indic
alveolar
epitheli
cell
could
simul
lung
fibrosi
vitro
thereaft
cell
cultur
without
condit
media
imrc
along
treatment
result
show
imrc
condit
media
significantli
amelior
induct
collagen
express
fig
immunofluoresc
western
blot
analys
confirm
imrc
condit
media
could
extinguish
collagen
protein
express
transdifferenti
fig
l
result
suggest
imrc
might
abl
inhibit
lung
fibrosi
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
tumorigen
long
obstacl
clinic
applic
cell
deriv
hesc
due
contamin
residu
hesc
could
form
teratoma
singl
cell
rna
sequenc
show
residu
hesc
remain
amongst
imrc
pluripot
gene
express
extinguish
fig
ensur
shortterm
term
safeti
seri
biosafetyrel
experi
perform
accord
guidelin
tabl
biosafetyrel
experi
includ
test
bacteria
fungi
mycoplasma
viru
vivo
vitro
method
pluripot
cell
residu
tumorigen
bioprepar
safeti
endotoxin
bovin
serum
albumin
residu
accord
test
safeti
imrc
verifi
requir
nation
track
biodistribut
longterm
engraft
imrc
vivo
wholeanim
imag
mice
perform
design
time
point
day
inject
dirlabel
imrc
data
show
dir
fluoresc
intens
declin
half
day
drop
steadili
least
day
disappear
around
day
fig
c
fig
dir
fluoresc
signal
observ
control
mous
result
indic
imrc
never
show
longterm
engraft
vivo
howev
imrc
predominantli
distribut
lung
small
amount
liver
spleen
fig
assess
recruit
imrc
lung
gfplabel
imrc
use
track
distribut
imrc
number
gfplabel
imrc
observ
interstiti
space
lung
lung
capillari
fig
immunofluoresc
analysi
express
alveolar
type
ii
epitheli
cell
marker
spc
endotheli
cell
marker
show
neither
marker
coexpress
gfplabel
imrc
lung
mice
day
fig
data
suggest
imrc
unlik
engraft
transdifferenti
endotheli
epitheli
cell
home
interstitium
lung
tissu
give
indic
tumorigen
potenti
imrc
vitro
soft
agar
assay
perform
fig
posit
control
pancrea
tumor
cell
line
show
coloni
format
rate
small
number
clone
also
form
hesc
coloni
format
rate
howev
coloni
form
imrc
result
indic
imrc
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
tumorigen
potenti
determin
assay
somat
mutat
analysi
whole
genom
sequenc
also
show
zero
mutat
code
noncod
exon
region
imrc
genom
fig
tumor
format
assay
also
confirm
imrc
could
form
tumor
immunodefici
mice
inject
vivo
supplementari
tabl
also
transfus
differ
dose
imrc
cynomolgu
monkey
macaca
fasciculari
evalu
shortand
longterm
toxic
imrc
primat
month
acut
toxic
data
show
blood
biochemistri
urinalysi
marker
remain
normal
rang
fig
h
indic
normal
liver
kidney
heart
muscular
pancreat
overal
metabol
function
moreov
abnorm
observ
longterm
toxic
test
either
fig
result
indic
imrc
robust
safeti
profil
vitro
vivo
anim
model
could
potenti
provid
therapeut
treatment
good
safeti
level
clinic
potenti
evalu
therapeut
effect
imrc
lung
injuri
fibrosi
imrc
administ
intraven
bleomycininduc
model
lung
injuri
imrc
amelior
total
bodi
weight
reduct
mice
expos
bleomycin
blm
induc
lung
injuri
dosedepend
manner
fig
kaplanmei
surviv
curv
indic
imrc
treatment
prolong
overal
surviv
rate
blm
group
vs
imrc
imrc
imrc
median
surviv
time
blm
group
vs
imrc
imrc
imrc
mice
expos
bleomycininduc
lung
injuri
statist
signific
differ
blm
group
imrc
group
group
fig
histolog
stain
lung
day
bleomycin
inject
inflamm
phase
show
diffus
pneumon
lesion
loss
normal
alveolar
architectur
septal
thicken
enlarg
alveoli
increas
infiltr
inflammatori
cell
interstiti
peribronchiolar
area
blm
lung
compar
normal
lung
imrc
treatment
reduc
alveolar
thicken
lung
dosedepend
manner
fig
moreov
imrc
treatment
reduc
number
macrophag
lung
fig
result
indic
imrc
treatment
reduc
inflamm
lung
acut
injuri
moreov
imrc
treatment
also
improv
ashcroft
score
pulmonari
fibrosi
dosedepend
manner
fig
particularli
imrc
treatment
decreas
collagen
deposit
blm
lung
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
depend
manner
fig
express
level
col
fn
also
signific
lower
imrc
treatment
fig
elisa
show
imrc
treatment
reduc
level
blm
lung
dosedepend
manner
fig
result
suggest
imrc
significantli
reduc
inflamm
fibrosi
lung
injuri
dosedepend
manner
pirfenidon
pfd
fdaapprov
drug
treatment
idiopath
pulmonari
fibrosi
work
reduc
lung
fibrosi
downregul
product
growth
factor
procollagen
ii
evalu
efficaci
imrc
treatment
compar
sidebysid
ucmsc
pfd
treatment
blminjur
mice
fig
result
show
imrc
treatment
led
improv
amelior
weight
reduct
blminduc
lung
injuri
compar
ucmsc
pfd
treatment
fig
kaplanmei
surviv
curv
indic
imrc
treatment
also
result
highest
overal
surviv
rate
compar
ucmsc
pfd
treatment
fig
blm
group
vs
imrc
p
ucmsc
pfd
moreov
imrc
treatment
show
best
improv
lung
morpholog
fig
best
reduct
blminduc
edema
measur
lung
coeffici
lung
wet
weighttot
bodi
weight
compar
ucmsc
pfd
treatment
fig
function
mice
treat
imrc
show
best
improv
indic
lung
capac
includ
pressurevolum
pv
inspiratori
capac
ic
static
complianc
cr
forc
vital
capac
fvc
fig
b
c
imrc
treatment
also
show
best
reduct
function
indic
lung
fibrosi
includ
respiratori
resist
rr
elast
resist
er
tissu
damp
g
tissu
elast
h
observ
fig
f
g
h
comput
tomographi
ct
scan
also
show
imrc
treatment
led
best
improv
lung
morpholog
compar
ucmsc
pfd
treatment
fig
j
fact
measur
lung
volum
indic
mice
treat
imrc
best
improv
lung
volum
compar
ucmsc
pfd
treatment
result
indic
imrc
therapi
superior
primari
ucmsc
pirfenidon
treat
lung
injuri
fibrosi
encourag
result
pilottest
imrc
transfus
compassion
treatment
two
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
sever
ill
patient
diagnos
ali
part
expand
access
program
patient
consent
imrc
administ
intraven
patient
within
day
imrc
transfus
patient
significantli
recov
pneumonia
test
neg
recommend
discharg
cytokin
analysi
patient
plasma
show
high
level
inflammatori
cytokin
initi
day
expect
induc
cytokin
storm
occur
point
treatment
fig
howev
day
mani
proinflammatori
cytokin
suppress
imrc
infus
includ
groa
mcsf
tnfa
fig
result
confim
imrc
manifest
hyperimmunomodulatori
function
signific
therapeut
benefit
ali
patient
without
treatment
option
studi
imrc
deriv
selfrenew
hesc
cultur
xenofre
reagent
result
show
imrc
similar
primari
ucmsc
superior
prolif
capac
hyperimmunomodulatori
antifibrot
function
addit
cell
diamet
imrc
gener
smaller
ucmsc
suggest
pose
lower
risk
pulmonari
embol
recent
year
msclike
cell
gener
hesc
use
variou
protocol
howev
best
knowledg
spite
signific
effort
numer
group
previous
report
studi
lack
biosafetyrel
experi
hinder
translat
clinic
applic
ensur
safeti
seri
biosafetyrel
experi
perform
accord
guidelin
human
somat
cell
therapi
qualiti
control
cellbas
product
imrc
verifi
suitabl
use
human
therapi
data
show
teratoma
format
observ
imrc
inject
test
nodscid
mice
addit
singl
cell
rna
sequenc
data
show
residu
hesc
detect
imrc
soft
agar
assay
also
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
show
coloni
form
imrc
addit
somat
mutat
analysi
whole
genom
sequenc
also
show
mutat
protooncogen
tumor
suppressor
gene
code
noncod
exon
region
imrc
result
indic
imrc
demonstr
potenti
form
tumor
moreov
imrc
could
undergo
longterm
engraft
disappear
around
day
imrc
transdifferenti
endotheli
cell
alveolar
epitheli
cell
lung
evalu
risk
clinic
applic
shortand
longterm
toxic
test
perform
cynomolgu
monkey
month
acut
toxic
test
longterm
toxic
test
data
show
abnorm
observ
result
prove
imrc
could
excel
safeti
profil
clinic
potenti
moreov
data
suggest
therapeut
efficaci
imrc
may
due
longterm
engraft
direct
repair
tissu
due
hyperimmunomodulatori
antifibrot
function
inflammatori
site
tissu
interstitium
like
msc
imrc
immunoprivileg
escap
immun
respons
lack
express
hla
class
ii
weak
express
hla
class
thu
make
valuabl
choic
allogen
cell
therapi
moreov
report
msc
could
releas
immunomodulatori
factor
alter
express
surfac
molecul
produc
growth
factor
immun
respons
inflammatori
cytokin
produc
cell
antigenpres
cell
immunomodulatori
factor
crucial
regul
immun
system
promot
tissu
repair
accordingli
express
cellsuppress
greatli
increas
imrc
stimul
proinflammatori
cytokin
even
ucmsc
genomewid
rna
sequenc
reveal
imrc
ucmsc
differ
express
profil
exposur
analysi
secretom
imrc
ucmsc
confirm
least
nine
proinflammatori
cytokin
lower
sever
antiinflammatori
cytokin
proregen
factor
higher
imrc
ucmsc
result
suggest
imrc
possess
immunomodulatori
capac
compar
primari
ucmsc
stimul
thu
cell
administ
immunocompet
anim
human
patient
without
need
immunosuppress
moreov
higher
level
secret
imrc
primari
ucmsc
play
import
role
process
fibrosi
degrad
exist
collagen
promot
earli
stage
tissu
remodel
critic
progress
fibrogenesi
gener
imbal
mmp
timp
direct
caus
fibrosi
tissu
scar
report
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
transplant
human
bone
marrowderiv
mesenchym
stem
cell
attenu
liver
fibrosi
rat
therefor
conceiv
imrc
highli
express
may
also
revers
lung
fibrosi
accordingli
data
show
secretom
imrc
could
reduc
collagen
level
fibrogenesi
induc
howev
still
unclear
whether
play
direct
role
decreas
collagen
futur
work
focu
role
use
imrc
vitro
vivo
mous
blm
model
similar
human
aliard
acut
inflammatori
phase
although
fibroblast
foci
alveolar
epitheli
type
cell
hyperplasia
honeycomb
lesion
reduc
compar
human
indic
reproduct
human
ard
complet
mous
blm
model
injuri
alveolar
epitheli
cell
shown
common
contribut
factor
pathogenesi
human
ard
blminduc
mous
pulmonari
injuri
test
therapeut
efficaci
imrc
blm
mous
model
deliveri
rout
schedul
administr
eg
singl
dose
versu
repeat
dose
care
consid
intraven
infus
one
princip
deliveri
rout
consid
minim
invas
simpletous
common
mode
primari
msc
deliveri
divers
lung
disord
furthermor
system
intraven
transplant
may
suitabl
administr
rout
futur
clinic
scenario
present
studi
intraven
imrc
improv
surviv
rate
mice
blminduc
lung
injuri
dosedepend
manner
inhibit
pulmonari
inflamm
fibrosi
demonstr
vitro
imrc
inhibit
product
proinflammatori
cytokin
profibrosi
cytokin
lung
tissu
vivo
furthermor
lung
function
indic
pv
ic
rr
cr
er
rn
g
h
fvc
improv
compar
blm
group
furthermor
pilot
test
imrc
transfus
clinic
confirm
imrc
could
rapidli
suppress
inflammatori
cytokin
storm
two
patient
within
day
sever
ill
patient
recommend
discharg
within
day
imrc
treatment
note
imrc
administ
day
initi
blminjuri
fibrosi
fulli
develop
fact
sever
studi
report
primari
msc
treatment
improv
pathologicallyestablish
pulmonari
fibrosi
studi
suggest
primari
msc
actual
exacerb
pulmonari
fibrosi
regard
efficaci
imrc
establish
fibrosi
studi
necessari
investig
still
ongo
unclear
whether
primari
msc
promot
pulmonari
fibrosi
lack
posit
therapeut
effect
may
due
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
